The Effectiveness of Nano Bio Fusion Gingival Gel (NBF) on Wound Healing at the Palate (Donor Site) After Soft Tissue Graft Surgery Compared to Placebo Gel.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Application of NBF gel after soft tissue graft surgery, Application of placebo gel after soft tissue graft surgery.
- Who it may be relevant to
- Registry conditions: Wound Healing, Palatal Wound, Donor Site Complication, Inflammatory Cytokines. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Jordan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Effectiveness of Nano Bio Fusion Gel (NBF) on Early Wound Healing at the Palate (Donor Site) After Soft Tissue Graft Surgery Compared to Placebo Gel: a Double Blinded Randomized Controlled Clinical Trial
Overview
The goal of this clinical trial is to assess the effect of Nano-biofusion gingival gel (NBF) on wound healing at the palatal donor site following soft tissue graft surgery and compare it to placebo gel. The main questions it aims to answer are: * Does NBF gel enhance wound healing after graft harvesting from the palate? * Does NBF gel reduce the number of inflammatory mediators after surgery? * Does NBF gel reduce pain and discomfort at the palatal donor site? Researchers will compare NBF gel to a placebo (a look-alike gel that does not contain the active ingredients) to see if NBF gel enhances wound healing. Study steps include: * Participants will apply the assigned gel on the surgical wound 4 times a day for 4 weeks. * Clinical photographs and measurements will be obtained on days (0, 1, 2, 4, 7, 15, 21, 30). * Wound fluid samples will be collected on days (0, 1, 2, 4, 7). * Participants will be asked about the level of pain and analgesic consumption on each follow-up visit.
Detailed description
A sample size of 36 subjects, with treated 18 sites in each group should be sufficient to detect a mean difference of 1 mm of the wound area between groups. Efforts will be made to balance the number of men and women in each group (if possible).
The participants will be recruited from patients coming to dental teaching clinics at Jordan University of Science and Technology. The patients will be randomly assigned into 2 groups using computer generated randomization sequence:
Group 1: placebo gel Group 2: NBF gel
The study's purpose and procedures will be clearly communicated to all patient. Prior to examination and treatment, each participant must sign a consent form.
Patients who require a soft tissue surgery to cover gingival recession around teeth, to modify the phenotype where there is a thin gingival tissue, or to increase the width and thickness of soft tissue will be included in the study. The soft tissue graft should be obtained from the palatal donor site by free gingival graft or depithelized connective tissue graft, leaving an open wound in the palate (around 3×6 mm size) that is going to heal by secondary intesntion.
After the procedure, patients will be instructed to use the gel 4 times a day for 4 weeks by applying it to the wound and massaging the area. It will be provided in a small opaque tube. One tube should be used each day. The clinician and the patient will be blinded to the type of gel used. Another doctor or dental assistant will be responsible for dispencing the gel to the patient according to the randomization sequence and the code sheet.
Oral hygiene measures will be prohibited for the first 2 weeks in the surgical area only to not disturb the wound healing. Patients should follow their oral hygiene routine for the rest of the teeth. They will be instructed to use 0.2% chlorhexidine mouth wash twice a day for 2 weeks after surgery.
The study will last for one month for each patient. Each patient will be assessed immediately before and after the surgery and on days (0, 1, 2, 4, 7, 15, 21, 30). Clinical photographs will be taken at each time point.
Wound fluid samples (WF) will be collected at the incision area immediately after surgery and wound closure (day 0) and on days (1, 2, 4, 7). Main inflammotry mediators will be assessed.
Study steps:
• T0(intervention): Pt will sign the consent form. Sof tissue graft surgery will be performed and the graft will be obtained from the palate. The surgery is not performed by one periodontist, but the assessment and measurements are done by the same blinded examiner.
• T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery): The wound will be measured to record all the primary and secondary outcomes. The exception is made for the collection of wound fluid samples on days 15, 21 and 30. As the wound will be probably closed by then, samples will not be collected, unless there is delayed wound healing and the fluid can be drawn from the wound.
Clinical photos will be taken before surgery and anesthesia, immediately after surgery and the rest of time points.
Interventions
- Drug Application of NBF gel after soft tissue graft surgery
After the surgery, patients will be instructed to apply the NBF gel to the donor site on the palate for four times daily for 4 weeks. If there is a vertical releasing incision in the recipient site, the gel will be applied along that incision too. The first application will be performed immediately after surgery by the investigator using a sterile cotton applicator. - Other Application of placebo gel after soft tissue graft surgery
After the surgery, patients will be instructed to apply the placebo gel to the donor site on the palate for four times daily for 4 weeks. If there is a vertical releasing incision in the recipient site, the gel will be applied along that incision too. The first application will be performed immediately after surgery by the investigator using a sterile cotton applicator.
Primary outcome measures
- Wound area [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
Secondary outcome measures (7)
- Early wound healing index (EWHI) [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- Present or abscent (Yes/no): [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- Erythema, redness + edema, swelling [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- Epithelization and exposure of CT [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- Incision margins [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- Patient reported outcome measure (PROM) [Time frame: On each follow up visit: T1 (24 hours after the surgery), T2 (2 days after the surgery), T3 (4 days after the surgery), T4 (7 days after the surgery), T5 (15 days after the surgery), T6 (21 days after the surgery), T7 (30 days after the surgery)]
- cytokine measurement using ELISA test [Time frame: Immediately after surgery and wound closure (day 0) and on days (1, 2, 4, 7). They will not be collected at days 15, 21, and 30 as the wound should be closed by then, unless there is delayed wound healing and the fluid can be collected from the wound.]
Eligibility criteria
Inclusion criteria
- Patients with gingival recession that is indicated for root coverage or need for phenotype modification.
- 18 years or older.
- absence of systemic disease
- Non-smoker
- No use of antibiotics, corticosteroids, anti-inflammatory medication or hormones in the past 3 months
Exclusion criteria
- Pregnant or lactating woman.
- patients with immune or systemic diseases.
- Patients with an allergy to any ingredient in the gel.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Supportive care
Study locations
Jordan · 1 center
- Jordan University of Science and Technology, Faculty of Dentistry — Irbid
Identifiers
NCT: NCT07330154 · 440-2025 · 2/185/2025